Renaissance IPO ETF (IPO) is rated a buy, anticipating a surge in major IPOs through 2026 to fuel renewed investor interest.

In this past year, we’ve seen the IPO market stabilize after several years of large-scale uncertainties – think post-COVID ...

Initial public offerings (IPOs) rank among the most closely followed events in the stock market. They inject new opportunities, and often renewed excitement, into the trading landscape. As a result, ...

Baidu plans a Hong Kong IPO spin-off of AI chip unit Kunlunxin, boosting valuation as AI/Cloud growth accelerates. See why ...

Through mid-November, the returns of initial public offerings have slowed, and the Renaissance IPO Index stands at a gain of 5.1% year to date, lagging the S&P 500 (up 16.4% by market price over the ...

When it comes to new IPOs, tech companies are always trying to sell themselves on their cutting-edge technology. But xTool ...

Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price of $15 to $17 per share. The California biotech announced its IPO intentions ...

Reflecting the moving tide from New York to Hong Kong, EV maker Zeekr delisted from the New York Stock Exchange in December, ...

Despite a U.S. government shutdown that hit the “pause” button on new initial public offerings, the IPO market is expected to finish 2025 as it started, with a flurry of newly minted publicly traded ...